Skip to main content
Erschienen in: Annals of Nuclear Medicine 6/2009

01.08.2009 | Original Article

Characterization of thymic masses using 18F-FDG PET-CT

verfasst von: Arvind Kumar, Subodh Kumar Regmi, Roman Dutta, Rakesh Kumar, Siddhartha Datta Gupta, Prasenjit Das, Dhanapathi Halanaik, Tarun Jindal

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The resectability and survival may be improved in thymoma and thymic carcinoma with multimodality therapy. Various diagnostic imaging modalities are required for accurate diagnosis and preoperative staging of thymic masses. The present prospective study was planned to evaluate if Fluorodeoxyglucose (FDG) PET-CT can help differentiate various thymic lesions noted on conventional imaging modalities.

Methods

A prospective study was undertaken in 23 patients who had shown either an anterior mediastinal mass consistent with thymic origin or suspicious for a thymic mass on contrast-enhanced computed tomography scan. All patients underwent whole body FDG PET-CT after intravenous injection of 370 MBq of FDG. The interpretation of PET-CT images was based on the following criteria: FDG uptake (present or absent), SUVmax, pattern of uptake, invasion to surrounding structures, presence of metastasis and necrosis. The results of PET-CT were correlated with the final histopathology following surgery. Statistical analysis was performed with SPSS 11.5 for Windows software. The mean SUVmax of the 3 groups of pathology was compared using the Kruskal–Wallis Test.

Results

Thymic hyperplasia had an enlarged thymus with mean SUVmax of 1.1. Low risk thymoma had large tumors and their mean SUVmax was 3. High risk thymoma had small tumors with mean SUVmax of 2.1. As a group, thymoma had mean SUVmax value of 2.3. All thymic carcinomas were large, and their mean SUVmax was 7. The difference between the mean SUVmax for thymic hyperplasia, thymoma and thymic carcinoma was statistically significant. The difference between the SUVmax of high risk and low risk thymoma was not significant.

Conclusion

18F-FDG PET-CT can help characterize various thymic lesions noted on conventional imaging modalities. However, larger prospective studies are further required to substantiate these findings.
Literatur
1.
Zurück zum Zitat Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48(11):2485–92.PubMedCrossRef Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48(11):2485–92.PubMedCrossRef
3.
Zurück zum Zitat Nakahara K, Ohno K, Hashimoto J, Maeda H, Miyoshi S, Sakurai M, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg. 1988;95(6):1041–7.PubMed Nakahara K, Ohno K, Hashimoto J, Maeda H, Miyoshi S, Sakurai M, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg. 1988;95(6):1041–7.PubMed
4.
Zurück zum Zitat Curran WJ Jr, Kornstein MJ, Brooks JJ, Turrisi AT 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722–7.PubMed Curran WJ Jr, Kornstein MJ, Brooks JJ, Turrisi AT 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722–7.PubMed
5.
Zurück zum Zitat Restrepo CS, Pandit M, Rojas IC, Villamil MA, Gordillo H, Lemos D, et al. Imaging findings of expansile lesions of the thymus. Curr Probl Diagn Radiol. 2005;34(1):22–34.PubMedCrossRef Restrepo CS, Pandit M, Rojas IC, Villamil MA, Gordillo H, Lemos D, et al. Imaging findings of expansile lesions of the thymus. Curr Probl Diagn Radiol. 2005;34(1):22–34.PubMedCrossRef
6.
Zurück zum Zitat de Kraker M, Kluin J, Renken N, Maat APWM, Bogers AJJC. CT and myasthenia gravis: correlation between mediastinal imaging and histopathological findings. Interact CardioVasc Thorac Surg. 2005;4:267–71.PubMedCrossRef de Kraker M, Kluin J, Renken N, Maat APWM, Bogers AJJC. CT and myasthenia gravis: correlation between mediastinal imaging and histopathological findings. Interact CardioVasc Thorac Surg. 2005;4:267–71.PubMedCrossRef
7.
Zurück zum Zitat Jeong YJ, Lee KS, Kim J, Shim YM, Han J, Kwon OJ. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? Am J Roentgenol. 2004;183:283–9. Jeong YJ, Lee KS, Kim J, Shim YM, Han J, Kwon OJ. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? Am J Roentgenol. 2004;183:283–9.
8.
Zurück zum Zitat Inaoka T, Takahashi K, Mineta M, Yamada T, Shuke N, Okizaki A, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869–76.PubMedCrossRef Inaoka T, Takahashi K, Mineta M, Yamada T, Shuke N, Okizaki A, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869–76.PubMedCrossRef
9.
Zurück zum Zitat McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther. 1995;66(3):465–505.PubMedCrossRef McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther. 1995;66(3):465–505.PubMedCrossRef
10.
Zurück zum Zitat Wahl RL. Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” result. J Nucl Med. 1996;37(6):1031–7. Wahl RL. Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” result. J Nucl Med. 1996;37(6):1031–7.
11.
Zurück zum Zitat Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22(12):1402–7.PubMedCrossRef Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22(12):1402–7.PubMedCrossRef
12.
Zurück zum Zitat Kubota K, Yamada S, Kondo T, Yamada K, Fukuda H, Fujiwara T, et al. PET imaging of primary mediastinal tumours. Br J Cancer. 1996;73(7):882–6.PubMed Kubota K, Yamada S, Kondo T, Yamada K, Fukuda H, Fujiwara T, et al. PET imaging of primary mediastinal tumours. Br J Cancer. 1996;73(7):882–6.PubMed
13.
Zurück zum Zitat Sasaki M, Kuwabara Y, Ichiya Y, Akashi Y, Yoshida T, Nakagawa M, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40(10):1595–601.PubMed Sasaki M, Kuwabara Y, Ichiya Y, Akashi Y, Yoshida T, Nakagawa M, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40(10):1595–601.PubMed
14.
Zurück zum Zitat Ohtsuka T, Nomori H, Watanabe K, Naruke T, Suemasu K, Kosaka N, et al. Positive imaging of thymoma by 11C-acetate positron emission tomography. Ann Thorac Surg. 2006;81:1132–4.PubMedCrossRef Ohtsuka T, Nomori H, Watanabe K, Naruke T, Suemasu K, Kosaka N, et al. Positive imaging of thymoma by 11C-acetate positron emission tomography. Ann Thorac Surg. 2006;81:1132–4.PubMedCrossRef
15.
Zurück zum Zitat Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628–34.PubMed Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628–34.PubMed
16.
Zurück zum Zitat El-Bawab H, Al-Sugair AA, Rafay M, Hajjar W, Mahdy M, Al-Kattan K. Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg. 2007;31:731–6.PubMedCrossRef El-Bawab H, Al-Sugair AA, Rafay M, Hajjar W, Mahdy M, Al-Kattan K. Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg. 2007;31:731–6.PubMedCrossRef
17.
Zurück zum Zitat Endo M, Nakagawa K, Ohde Y, Okumura T, Kondo H, Igawa S, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61(3):350–5.PubMedCrossRef Endo M, Nakagawa K, Ohde Y, Okumura T, Kondo H, Igawa S, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61(3):350–5.PubMedCrossRef
18.
Zurück zum Zitat Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328–34.PubMedCrossRef Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328–34.PubMedCrossRef
19.
Zurück zum Zitat Meltzer CC, Leal JP, Mayberg HS, Wagner HN Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr. 1990;14(4):561–70.PubMedCrossRef Meltzer CC, Leal JP, Mayberg HS, Wagner HN Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr. 1990;14(4):561–70.PubMedCrossRef
20.
Zurück zum Zitat Chen CH, Muzic RF Jr, Nelson AD, Adler LP. Simultaneous recovery of size and radioactivity concentration of small spheroids with PET data. J Nucl Med. 1999;40(1):118–30.PubMed Chen CH, Muzic RF Jr, Nelson AD, Adler LP. Simultaneous recovery of size and radioactivity concentration of small spheroids with PET data. J Nucl Med. 1999;40(1):118–30.PubMed
21.
Zurück zum Zitat Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904–11.PubMed Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904–11.PubMed
22.
Zurück zum Zitat Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267–74.PubMedCrossRef Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267–74.PubMedCrossRef
Metadaten
Titel
Characterization of thymic masses using 18F-FDG PET-CT
verfasst von
Arvind Kumar
Subodh Kumar Regmi
Roman Dutta
Rakesh Kumar
Siddhartha Datta Gupta
Prasenjit Das
Dhanapathi Halanaik
Tarun Jindal
Publikationsdatum
01.08.2009
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2009
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0283-z

Weitere Artikel der Ausgabe 6/2009

Annals of Nuclear Medicine 6/2009 Zur Ausgabe